Adverse Event Reporting
| VAERS ID | 925639 |
|---|---|
| Gender | Female |
| Age | 34 |
| StateCode | ID |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | EL0140 |
| Number of vaccinations | 1 |
| Vaccinated | 2020-12-22 |
| Onset | 2020-12-22 |
| Condition |
Symptoms
- Exposure during pregnancy
- Abortion spontaneous
Current Illness
Sleep apnoea
Preexisting Conditions
Other Medications
Previous Vaccinations
Allergies
Laboratory Data
Test Name: tested for COVID-19; Result Unstructured Data: Test Result:Unknown results; Test Date: 20201228; Test Name: Nasal Swab; Test Result: Negative
Write-up
Miscarriage; patient was pregnant while taking BNT162B2; patient was pregnant while taking BNT162B2; This is a spontaneous report from a contactable Other Health Professional.
A 34-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: EL0140), intramuscularly on 22Dec2020 06:00 AM at single dose at Arm Right at Hospital for COVID.
Medical history included ongoing sleep apnoea.
There were no concomitant medications.
There were no allergies to medications, food, or other products.
The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.
The patient did not receive any other medications the patient received within 2 weeks of vaccination.
Prior to vaccination, the patient was not diagnosed with COVID-19.
The patient experienced miscarriage on 29Dec2020 13:00.
The patient was pregnant while taking BNT162B2.
The patient was 4 Weeks pregnant at the onset of the event.
Patient last menstrual period date was 24Nov2020.
The Pregnancy due to deliver was on 07Sep2021.
The pregnancy resulted in spontaneous abortion.
Since the vaccination, the patient has been tested for COVID-19 on an unknown date with unknown results.
Nasal Swab on 28Dec2020 was Negative.
There was no treatment received for the adverse event.
The outcome of event was recovering.
; Sender's Comments: The information currently provided is too limited to make a meaningful medical assessment hence, the events are conservatively assessed as related to the suspect drug BNT162B2 until further information becomes available.
The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events.
Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to agency, Ethics Committees, and Investigators, as appropriate.